[1] Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology, 49:1017-1044.
[2] Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol, 2003, 29: 1705-1713.
[3] Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther, 2016, 43:458-469.
[4] Xu Q, Sheng L, Bao H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol, 2017,32:639-644.
[5] Hashemi SA, Alavian SM, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Int Med, 2016, 7:242-252.
[6] Pavlov CS, Casazza G, Nikolova D, et al. Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Aliment Pharmacol Ther, 2016, 43:575-585.
[7] Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol, 2011, 54:650-659.
[8] Kim SU, Park JY, Kim DY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int, 2010, 4:673-680.
[9] Kim MN, Kim SU, Kim BK, et al. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int, 2014, 34:1216-1223.
[10] Jang W, Yu SI, Shin DH, et al. Longitudinal change of liver stiffness by transient elastography in chronic hepatitis B patients treated with nucleos(t)ide analogue. Clinics and Research in Hepatology and Gastroenterology, 2014, 38:195-200.
[11] Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med, 2018, 18:273-282.
[12] Ogasawara N, Kobayashi M, Akuta N, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acing antiviral therapy against hepatitis C virus genotype 1b. J Med Virl, 2008, 90:313-319.
[13] Elshakawy A, Alem SA, Fouad R, et al. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol, 2017, 32:1624-1630.
[14] D’ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol, 2013, 59:251-256.
[15] Paul J, Venugopal RV, Peter L, et al. Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with nonalcoholic fatty liver disease. Gastoenterol Rep, 2018, 6:49-53.
[16] Hartl J, Denzer U, Ehlken H, et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol, 2016, 65:769-775.
[17] Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypentension. J Hepatol, 2016, 65:692-699.
[18] Robic MA, Procopet B, Metivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol, 2011, 55:1017-1024.
[19] Shi KQ, Fan YC, Pan ZZ, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int, 2013, 33:62-71.
[20] Li T, Qu Y, Yang B, et al. Evaluation of large esophageal varices in cirrhotic patients by transient elastography: a meta-analysis. Rev Esp Enferm Dig, 2016, 108:464-472.
[21] Pu K, Shi JH, Wang X, et al. Diagnostic accuracy of transient elastography (FibroScan) in detection of esophageal varices in patients with cirrhosis: A meta-analysis. World J Gastroenterol, 2017, 23:345-356.
[22] Chen YP, Zhang Q, Dai L, et al. Is transient elastography valuable for high risk esophageal varices prddiction in patients with hepatitis-B-related cirrhosis?J Gastroenterol Hepatol, 2012, 27:533-539.
[23] Par G, Trosits A, Pakodi F, et al. Transient elastography as a predictor of oesophageal varices in patients with liver cirrhosis. Orv Hetil, 2014, 155:270-276.
[24] Lampertico P, Invernizzi F, Vigano M, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. J Hepatol, 2015, 63:1118-1125.
[25] Piecha F, Paech D, Sollors J, et al. Rapid change of liver stiffness after variceal ligation and TIPS implantation. Am J Physiol Gastrointest Liver Physiol, 2018, 314:G179-G187.
[26] Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatol, 2009, 49:1954-1961.
[27] Jung KS, Kim SU, Ahn SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (fibroscan) . Hepatol, 2011, 53:885-894.
[28] Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatol, 2015, 61:1851-1859.
[29] Wang HM, Hung CH, Lu SN, et al. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int, 2013, 33:756-761.
[30] Tatsumi A, Maekawa S, Sato M, et al. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res, 2015, 45:523-532.
[31] Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol, 2014, 60:339-345.
[32] Kim BS, Seo YS, Kim YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. J Gastroenterol Hepatol, 2018, 33:503-510.
[33] Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrence fibrosis after liver transplantation: A meta-analysis. PLoS One, 2017, 12:e0185192.doi:10.1371/journal.pone.0185192.
[34] Crepo G, Lens S, Gambato M, et al. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrence hepatitis C. Am J Transplat, 2014, 14:375-383. |
